June 15, 2016
Novo Nordisk’s Victoza (liraglutide) became the first glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate reductions in cardiovascular risks in diabetes patients, and the second diabetes drug to do so, after Jardiance (empagliflozin) , with a reduction of 13%, according to...read more